Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
about
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).Points to consider when doing a trial primarily involving the heart.TNIP1 in Autoimmune Diseases: Regulation of Toll-like Receptor SignalingSystemic sclerosis: state of the art on clinical practice guidelines
P2860
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
@en
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
@nl
type
label
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
@en
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
@nl
prefLabel
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
@en
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
@nl
P2093
P2860
P356
P1433
P1476
Interstitial lung disease points to consider for clinical trials in systemic sclerosis
@en
P2093
Athol Wells
Daniel E Furst
Dinesh Khanna
Donald P Tashkin
James Seibold
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEX203
P433
P577
2017-09-01T00:00:00Z